A Phase 1/2 interventional study of PASC transplantation (25 million PASCs/patient) and Control in Parkinson Disease, sponsored by ClusterXStem-Costa Rica. Active, not recruiting at 2 sites in Costa Rica. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-12-01.
Sponsored by ClusterXStem-Costa Rica · Phase 1/2, Interventional, and Treatment
The purpose of this study is to assess the safety and efficacy of allogenic pluripotent stem cells isolated from adipose tissue (PASCs) in patients with Parkinson's Disease.
Pluripotent Adipose-Derived Stem Cells (PASCs) will be delivered intravenously at a dosage of 25 million PASCs/patient to Parkinson's Disease patients for three infusions each spaced 3 months apart (0, 3, and 6 months). Safety and efficacy of PASC treatment will be monitored over 0, 1, 3, 6, and 12 months.
4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.
This study's enrollment of 40 is close to the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →This is the only study on the registry with ClusterXStem-Costa Rica as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Abnormal laboratory values, including:
Pluripotent Adipose-Derived Stem Cells will be delivered intravenously
Biological: PASC transplantation (25 million PASCs/patient)
Saline solution will be delivered intravenously
Biological: Control
3 doses of 25 million PASCs implantation via peripheral vein (Day 0, 3 months, 6 months)
0.9% saline solution via peripheral vein (Day 0, 3 months, 6 months)
Change in motor function as assessed by the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score
The MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a widely used research tool to quantify the clinical characteristics of PD in adults. This scale assesses various aspects of Parkinson's disease, including motor and non-motor experiences of daily life and motor complications. This test will take approximately 30 minutes, assessing the impact of the disease in 4 different domains distributed in 65 items, of which 48 are scored from 0 to 4 and seven with dichotomous answers of "yes" or "no". The global range of the MDS-UPDRS will be from 0 to 260 points, the higher the score, the greater the disease involvement.
Time frame: Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Quality of life as assessed by the 39-item Parkinson's disease Questionnaire (PDQ-39)
The 39-item Parkinson's disease Questionnaire (PDQ-39) is the most widely test used to assess specific quality of life questionnaire for Parkinson's disease, and it has been validated and cross-culturally translated. The questionnaire consists of 39 questions to be completed by the patient, that assesses the frequency in which patients with PD experience difficulties in 8 dimensions of functionality and well-being: mobility, activities of daily living, emotional well- being, attention and memory, social support, depression, cognition, communication and social relationships. Items can be transformed on a linear scale from 0 to 100, the higher the score reflects a lower quality of life.
Time frame: Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Speech voice sound and duration
Since most people with Parkinson's disease (PD) have voice and speech disorders that result in harmful effects on communication and quality of life; the measurement of the pressure level and sound duration will be executed using the Samson Go Mic and the software used for the Lee Silverman Voice Treatment Therapy (LSVT LOUD).
Time frame: Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Dynamic balance and movement during translational motion and single-limb stance in seconds as assessed by the Mini Balance Evaluation Systems Test (mini BESTest)
The Mini Balance Evaluation Systems Test (mini BESTest) has proven to be a reliable and valid measurement tool for patients with PD. It is aimed to measure dynamic balance and associated movement during translational motion. The test consists of 14 items, with a maximum score of 28 points, with a higher test result, the greater the patient's functionality 35 . The test has high inter-rater reliability (ICC = 0.92) and high test-retest reliability (ICC = 0.92) for PD patients.
Time frame: Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Balance as assessed by the The Five-times Sit-to-stand Test
The Five-times sit-to-stand Test is a tool that quantifies the ability of patients suffering from diseases associated with balance problems, as in the case of PD, to perform transitional motions. In addition, it has been used as a measure of lower limb strength. The test has excellent inter-rater reliability and high test-retest reliability, as well as assessing for the risk of falls in patients with PD.
Time frame: Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Mobility and fall risk as assessed by the Timed "Up & Go" test
The Timed "Up \& Go" test consists of observing and timing the patient as he gets up from an armchair, walking for 3 meters, turns, returns and sits down again. The results of this test correlates well with the logarithmic transformation scores on the Berg Balance Scale, gait speed and the Barthel Index of AVD (Activities of Daily Living), and can predict the patient's ability to walk alone safely.
Time frame: Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Balance and postural stability as assessed by the Clinical test of Sensory Interaction & Balance Test (CTSIB), stability limits, and unipodal balance test
Computerized posturography using a force platform system provides objective and quantitative evaluations of deficiencies in postural control. The participants of the present study will be subjected to two tests of balance and postural stability using the HUMAC®43 brand force platform system. Three tests will be performed: CTSIB test (Clinical test of Sensory Interaction \& Balance), the stability limits, and the unipodal balance test.
Time frame: Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Tremor and handwriting
Alterations in the kinematics of handwriting are among the recently proposed biomarkers of PD. Recent studies have suggested the potential of handwriting analysis for both early diagnosis and assessment of disease progression. In the present study, the patients will be subjected to 5 tests, at 5 different times of the study using the MovAlyzeR® software in conjunction with the WACOM ONE tablet, to measure the speed, amplitude, fluidity and tremor of the movements of the upper extremities.
Time frame: Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Grip strength
The decrease in grip strength is a predictor of adverse outcomes in older adults and will be determined using a Jamar brand digital dynamometer to measure the grip strength of the patients participating in each assessment.
Time frame: Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Dynamic balance in the bipedal as measured by the 360 degree turn test
This test measures dynamic balance in the bipedal. In this test, the number of steps and the time that take the patient to make a complete 360-degree turn will be measured.
Time frame: Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Adverse events upon clinical examination
Study participants will be examined for clinical signs of adverse events.
Time frame: Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Optimal number of doses of 2.5 x 10^7 PASCs for therapeutic response
The optimal number of doses of PASCs for therapeutic response will be measured.
Time frame: Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Plan to share: No
This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.